Needham Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $55
Needham Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $55
Needham維持對rhythm pharmaceuticals的買入評級，將目標價提高至55美元。
Needham analyst Joseph Stringer maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $46 to $55.
Needham分析師Joseph Stringer給Rhythm Pharmaceuticals (納斯達克:RYTM)評爲買入，並將目標價從46美元上調至55美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。